Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.
Dr. Delaney brings to Coeptis more than two decades of experience as a trained oncologist and stem cell transplant physician scientist with expertise in the translation of scientific discovery to clinical practice, including all aspects of cell therapy product development, from initial discovery to pre-clinical and Investigational New Drug (IND)-enabling studies, manufacturing, global regulatory experience, and clinical trial design. She has served on a multiple cell and gene therapy focused federal advisory committees and as a Director for several nonprofit associations.
In addition to her industry experience, Dr. Delaney is a Clinical Professor at the University of Washington, Division of Pediatric Hematology/Oncology, and is an Affiliate and former Professor at the Fred Hutch, where she also held the Madeline Dabney Adams Endowed Chair in AML research. She earned her MSc from Oxford University and her MD from Harvard Medical School.
“Dr. Delaney is a visionary researcher who has dedicated her life to patients as a practicing physician and through her career as a global leader advancing all aspects of cell therapy product development,” said Dave Mehalick, President and CEO of Coeptis Therapeutics. “Colleen’s work with Deverra and the impressive pipeline of technologies she developed demonstrate her ingenuity and scientific acumen. Coeptis is excited to benefit from Colleen’s unrivaled expertise and industry knowledge as we seek to maximize the combined technologies of Coeptis and Deverra to bring to the market impactful off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases.”
“I’m thrilled to join Coeptis as we build an industry leading pipeline of cell therapy technologies for a variety of cancers,” said Dr. Delaney. “Our team at Deverra laid a strong scientific foundation, and I’m confident that together with the novel and creative thinking at Coeptis, we can make substantial strides in delivering new treatments to patients and bring value to shareholders.”
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis’ business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.
